Related Experiment Video
Updated: May 30, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelets in secondary stroke prevention
1Department of Neurology, Volyn Regional Clinical Hospital Lutsk, Ukraine.
Frontiers in Neurology
|July 21, 2011
Summary
For secondary stroke prevention, antiplatelet therapies like aspirin and clopidogrel are key. Individualizing treatment is crucial, as current evidence doesn't favor one agent over another for atherothrombotic ischemic stroke.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atherothrombotic ischemic stroke poses a significant health burden.
- Secondary prevention strategies are vital to reduce recurrence.
- Antiplatelet agents are the cornerstone of secondary stroke prevention.
Purpose of the Study:
- To provide evidence-based recommendations for secondary prevention of atherothrombotic ischemic stroke.
- To review current antiplatelet therapies and their efficacy.
- To highlight the importance of personalized antiplatelet treatment approaches.
Main Methods:
- Systematic review of published studies on antiplatelet therapy for secondary stroke prevention.
- Analysis of data concerning aspirin resistance and clopidogrel metabolism.
- Evaluation of clinical trial outcomes for commonly used antiplatelet agents.
Main Results:
- Aspirin, clopidogrel, and extended-release dipyridamole are primary antiplatelet agents.
- Advances in understanding aspirin resistance and clopidogrel metabolism have been noted.
- Current evidence does not support a universal recommendation for one antiplatelet agent over others.
Conclusions:
- Individualizing antiplatelet therapy is essential for effective secondary stroke prevention.
- Further research may clarify optimal agent selection based on patient-specific factors.
- A tailored approach to antiplatelet treatment is recommended for atherothrombotic ischemic stroke.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...